German China India

Biotech Acquisition

Sanofi to Buy Ablynx for 4.8 Billion Dollars

| Editor: Ahlam Rais

Sanofi aims to strength the company’s R&D strategy with this acquisition.
Gallery: 1 image
Sanofi aims to strength the company’s R&D strategy with this acquisition. (Bild: Deposit Photos)

French pharma company, Sanofi aims to strengthen company’s R&D strategy with the acquisition of Nanobodies specialist Ablynx.

Paris/France – Sanofi has entered into a definitive agreement to buy Belgian biotech company Ablynx for approximately 4.8 billion dollars. Ablynx specialises in the discovery and development of Nanobodies. Hence, with this acquisition, Sanofi aims to strength the company’s R&D strategy.

The French company will also acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (ADSs), warrants and convertible bonds of Ablynx at a price per Ablynx share of 56 dollars in cash. The transaction was unanimously approved by the Boards of Directors of both the organisations.

Comments are being loaded ....

Leave a comment

The comment is checked by an editor and will be released soon.

  1. Avatar
    Avatar
    Edited by at
    Edited by at
    1. Avatar
      Avatar
      Edited by at
      Edited by at

Comments are being loaded ....

Report comment

Kommentar Freigeben

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

Freigabe entfernen

Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

copyright

This article is protected by copyright. You want to use it for your own purpose? Infos can be found under www.mycontentfactory.de (ID: 45115336 / Pharma & Food)